Stock listing

HKEX:2509 Qyuns Therapeutics Co., Ltd. (荃信生物) 股價

Home listing (HKEX) of Qyuns Therapeutics Co., Ltd.

Follow Qyuns Therapeutics Co., Ltd. into a list and get an email when it puts out news.

Share price · HKEX:2509

$13.01 HKD -1.58 (-10.8%)

Close on Nov 20, 2026

Past year -38.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$13.00 – $14.00 HKDNov 20, 2026
Volume
26,200 sharesNov 20, 2026
Market cap
$2.91B HKDAt the close on Nov 20, 2026 · price × 223.4M shares outstanding
52-week range
$13.00 – $24.50 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.75M HKDMedian day 42,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Qyuns Therapeutics Co., Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2509 · Home$13.01 HKD-1.58 (-10.8%)26,200$14.00$14.00$13.00$14.59Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2509 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$13.01-1.58-10.8%$14.00$14.00$13.0026,200
$14.59-0.01-0.1%$14.60$14.60$14.591,200
$14.60+0.20+1.4%$14.60$14.97$14.6099,400
$14.40-0.30-2.0%$14.42$14.56$14.4030,000
$14.70-0.19-1.3%$14.65$14.70$14.626,200
$14.89+0.28+1.9%$14.99$15.30$14.7217,000
$14.61-0.05-0.3%$14.50$14.79$14.5022,400
$14.66+0.16+1.1%$14.52$14.70$14.4124,000
$14.50+0.17+1.2%$14.38$15.09$14.388,600
$14.33-0.47-3.2%$16.00$16.00$14.33124,140
$14.80-0.06-0.4%$14.86$15.75$14.6670,400
$14.86-0.14-0.9%$14.68$15.13$13.78144,600
$15.00-0.25-1.6%$14.90$15.28$14.8729,000
$15.25-0.05-0.3%$15.80$15.80$14.8023,800
$15.300.000.0%$16.08$16.08$15.306,200
$15.30+0.12+0.8%$15.80$15.80$14.8687,800
$15.18-1.03-6.4%$15.80$15.80$14.8687,800
$16.21-0.39-2.3%$16.38$16.64$15.70768,600
$16.60+0.06+0.4%$15.81$16.70$15.8058,400
$16.54-0.02-0.1%$16.07$16.60$16.0758,400
$16.56-0.18-1.1%$16.00$16.56$16.0060,800
$16.74+0.54+3.3%$16.20$16.74$15.8742,800
$16.20+0.20+1.2%$16.02$16.40$15.40112,200
$16.00+0.50+3.2%$15.84$16.67$15.48638,000
$15.50-0.52-3.2%$16.10$16.10$15.3091,200
$16.02-0.40-2.4%$16.39$16.61$16.02615,000
$16.42-0.34-2.0%$16.71$16.90$16.4152,600
$16.76-0.24-1.4%$17.00$17.10$16.62250,000
$17.000.000.0%$16.88$17.00$16.7814,600
$17.00-0.29-1.7%$16.95$17.12$16.8026,200
$17.29-0.19-1.1%$17.29$17.30$17.0537,800
$17.48+0.10+0.6%$17.38$17.78$17.21127,400
$17.38+0.38+2.2%$18.00$18.00$16.86137,600
$17.00+0.05+0.3%$16.79$17.20$16.7934,200
$16.95+0.13+0.8%$16.82$17.17$16.6964,400
$16.82-0.35-2.0%$16.82$16.84$16.821,000
$17.17+0.40+2.4%$16.51$17.17$16.511,800
$16.77-0.11-0.7%$16.63$16.96$16.4123,800
$16.88-0.17-1.0%$17.01$17.01$16.819,800
$17.05+0.05+0.3%$17.58$17.63$16.7268,400
$17.00+0.10+0.6%$16.91$17.00$16.6629,600
$16.90+0.15+0.9%$17.24$17.50$16.6644,800
$16.75+0.18+1.1%$16.57$16.75$16.3619,400
$16.57+0.12+0.7%$16.40$16.60$16.403,000
$16.45-0.16-1.0%$16.46$16.90$16.3476,000
$16.61+0.08+0.5%$16.45$16.80$16.454,000
$16.53+0.29+1.8%$16.00$17.77$16.001,598,600
$16.24-0.18-1.1%$16.17$16.80$16.00125,200
$16.42+0.08+0.5%$16.48$16.84$16.0524,600
$16.34-0.16-1.0%$16.40$16.90$16.3030,800
$16.50+0.05+0.3%$16.54$16.54$16.1520,600
$16.45+0.01+0.1%$16.59$16.90$16.4528,200
$16.44-0.29-1.7%$16.90$16.93$16.41101,400
$16.73+0.37+2.3%$16.45$16.73$16.3741,600
$16.36+0.07+0.4%$16.33$16.70$16.10105,200
$16.29-0.37-2.2%$16.46$16.51$16.1686,600
$16.66-0.34-2.0%$17.02$17.02$16.6629,800
$17.00-0.19-1.1%$17.01$17.47$17.0011,200
$17.19+0.37+2.2%$16.77$17.50$16.7631,200
$16.82-0.28-1.6%$17.13$17.40$16.8078,000
$17.10+0.22+1.3%$17.20$17.50$17.1077,600
$16.88-0.09-0.5%$16.97$17.00$16.538,200
$16.97+0.19+1.1%$16.78$17.04$16.5847,400
$16.78+0.38+2.3%$17.30$17.30$16.68154,000
Ticker
HKEX:2509
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
HKEX
Currency
HKD

What changed lately

Latest news

Documents on Display

Oct 27, 2026

Closed $15.18 (-6.4%) on Oct 28, 2026

All Qyuns Therapeutics Co., Ltd. news

Qyuns Therapeutics Co., Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 16 in all · newest Nov 13, 2026 · oldest 2025
Decks
5 decks · latest August 2026

Where Qyuns Therapeutics Co., Ltd. is listed

ListingExchangeCountryCurrency
HKEX:2509 荃信生物 · Home listing · This pageHKEXHong KongHKD
OTC:QYUNFOTCUnited StatesUSD

Valuation

P/E 4.5× against a median of 15.3×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$2.98B HKD
P/E
4.5×
EV/sales
2.5×
EV/EBITDA
4.2×
Price/book
2.9×
Gross margin
88.6%
Operating margin
54.5%
Net margin
53.3%
Debt to equity
0.8×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509US$370.7MUS$380.5M4.5×2.5×4.2×2.9×53.3%0.8×n/a
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378US$387.5MUS$316.0Mn/an/an/a4.1×n/a0.1×n/a
Opus Genetics, Inc. · NASDAQ:IRDUS$385.7MUS$332.3Mn/a42.0×n/a10.0×n/a0.9×1.01
Eupraxia Pharmaceuticals, Inc. · TSX:EPRXUS$384.3MUS$252.7Mn/an/an/a2.9×n/a0.0×1.53
Hinova Pharmaceuticals, Inc. Class A · SSE:688302US$381.1MUS$285.9Mn/a23.0×n/a2.6×−167.3%0.1×n/a
Rezolute, Inc. · NASDAQ:RZLTUS$379.2MUS$289.9Mn/an/an/a4.4×n/a0.0×1.28
Phathom Pharmaceuticals, Inc. · NASDAQ:PHATUS$378.8MUS$359.8Mn/a1.3×n/an/a−30.2%n/a1.08
Puma Biotechnology Inc · NASDAQ:PBYIUS$364.5MUS$255.9M15.3×1.1×5.8×2.5×10.3%0.0×0.88
PureTech Health PLC · LSE:PRTCUS$364.3MUS$160.3Mn/a34.4×n/a0.9×n/a0.1×n/a
Lumosa Therapeutics Co Ltd · TPEX:6535US$362.3MUS$343.1Mn/a329×n/a9.7×n/a0.0×n/a
Aspen Neuroscience, Inc. · NASDAQ:ASPEUS$361.2MUS$288.8Mn/an/an/an/an/an/an/a
Median of the othersUS$379.0MUS$289.3M15.3×28.7×5.8×3.5×−30.2%0.0×1.08

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
33.00 HKD · Analysts' mean
EPS, year to Dec 2026
1.22 · 2 analysts
Revenue, year to Dec 2026
628.5M · 2 analysts

Team and board

Officers

OfficerRole
Hu YanbaoBoard Secretary and Joint Company Secretary
Lin WeidongExecutive Director and Deputy General Manager of Our Company
Qiu JiwanExecutive Director,Chairman of Our Board and General Manager of Our Company
Wu YiliangExecutive Director and General Manager of Cellularforce

Board

DirectorRole
Qiu JiwanExecutive Director,Chairman of Our Board and General Manager of Our Company
Hu YanbaoBoard Secretary and Joint Company Secretary
Lin WeidongExecutive Director and Deputy General Manager of Our Company
Wu YiliangExecutive Director and General Manager of Cellularforce

Decks

DeckKindSlidesDate
H1 2026 Earnings PresentationEarnings32 slidesAugust 2026
FY2025 Earnings PresentationEarnings34 slidesMar 31, 2026
H1 2025 Earnings PresentationEarnings31 slidesAug 19, 2025
FY2024 Earnings PresentationEarnings34 slidesMar 31, 2025
H1 2024 Earnings PresentationEarnings31 slidesAug 16, 2024

Open Decks

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue786.1M158.8M14.8M9.66M21.3M
Cost of revenue121.4M66.6M35.7M35.5M30.9M
Gross profit664.7M92.2M-33.0M9.66M-9.56M
Research and development239.2M334.3M364.4M257.2M151.9M
Selling, general and administrative99.8M115.9M164.6M76.6M24.0M
Operating income319.7M-326.4M-504.5M-293.7M-168.6M
Depreciation and amortization32.1M32.7M32.3M30.5M25.6M
EBITDA351.8M-293.7M-472.2M-263.1M-143.0M
Interest expense21.6M23.4M16.8M18.7M17.8M
Income before tax299.4M-349.8M-521.3M-312.4M-426.5M
Income tax71.1K-73.0K-73.0K-73.0K-73.0K
Net income306.3M-335.6M-507.7M-298.2M-411.0M
Earnings per share, basic1.37-1.53-2.47-1.34-1.85

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents962.2M360.7M216.3M213.1M218.1M
Short-term investments80.3M195.4M160.4M450.3M402.4M
Receivables19.9M26.9M364.0K662.0K354.0K
Inventory38.1M3.34M3.77M0
Current assets1.12B616.7M418.3M714.0M648.3M
Property, plant and equipment334.1M363.2M389.0M
Total assets1.60B983.9M795.6M1.16B1.07B
Accounts payable96.8M110.9M73.0M19.1M12.6M
Current liabilities504.0M430.2M251.8M122.2M69.7M
Long-term debt399.4M315.1M224.4M232.5M274.0M
Total debt580.3M527.6M346.1M295.3M290.3M
Total liabilities921.6M762.8M494.6M373.7M363.3M
Shareholders' equity694.3M229.0M294.8M641.7M670.4M
Shares outstanding223.7M219.4M205.7M222.1M222.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations399.8M-186.1M-300.7M-225.2M-122.6M
Capital spending-7.62M-1.76M-7.95M-26.5M-71.0M
Free cash flow392.2M-187.9M-308.6M-301.7M-228.6M
Cash from investing118.7M-25.2M243.1M-5.70M-247.4M
Cash from financing93.7M351.8M61.2M211.5M281.5M
Share buybacks-27.2M196.5M29.5M228.0M
Change in cash601.1M144.4M3.21M-4.96M-91.2M

Open Financials

Filings

FilingDateTypeFiled with
SUPPLEMENTAL AGREEMENT TO THE CDMO SERVICES FRAMEWORK AGREEMENT AND REVISION OF ANNUAL CAP AND RENEWAL OF ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONSNov 13, 2026Material contractHKEX
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONSNov 13, 2026List of directorsHKEX
(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 13, 2026&#x3b; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR&#x3b; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEENov 13, 2026Meeting outcomeHKEX
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS FOR A PRECLINICAL BISPECIFIC ANTIBODY PROGRAM TARGETING TL1A AND IL-17Nov 5, 2026Other filingsHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 5, 2026Monthly returnHKEX
Documents on DisplayOct 27, 2026Notification letterHKEX
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, NOVEMBER 13, 2026Oct 27, 2026Proxy formHKEX
NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETINGOct 27, 2026Meeting noticeHKEX
(1) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT&#x3b; (2) PROPOSED APPOINTMENT OF DIRECTOR AND DETERMINATION OF THE DIRECTOR'S REMUNERATION&#x3b; AND (3) NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETINGOct 27, 2026Meeting noticeHKEX
ANNOUNCEMENT BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETINGOct 26, 2026Meeting noticeHKEX
All 15 filings
FilingDateTypeFiled with
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 7, 2026Monthly returnHKEX
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY RESULTS OF OTURKIBART (QX005N) FOR TREATMENT OF PRURIGO NODULARIS PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT EADV 2026Oct 1, 2026Other filingsHKEX
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONSSep 22, 2026List of directorsHKEX
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT&#x3b; AND RESIGNATION AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTORSep 22, 2026Management or board changeHKEX
2026 INTERIM REPORTSep 21, 2026Interim reportHKEX

Open Filings

Cap table

Built by 6ix from Qyuns Therapeutics Co., Ltd. Class H’s releases

Common shares
223,369,200
Fully diluted
223,369,200

Fully diluted

LineShares
Common shares223,369,200

Share count over time

CountShares
Nov 22, 2026223,369,200

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Avantis Emerging Markets Equity Fund17,400US$37,443May 31, 2026
Emerging Markets Social Core Equity Portfolio10,400US$21,656Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Qiu JiwanExecutive Director,Chairman of Our Board and General Manager of Our Company · Since at least Jun 16, 2025

Open People

Log in to ask 6ix AI your own questions about Qyuns Therapeutics Co., Ltd.